The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...
ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in patients with aggressive B Cell No ...
It is the first CAR-T that the agency has said is safe for this hard-to-treat subset of lymphoma patients based on data from an investigator-initiated study.
Santa Monica, California Monday, February 9, 2026, 12:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results